Blog Band - Page 106 of 262 - PharmaShots

Skip to content Skip to footer

Login orRegister

Innovent Biologics Collaborates with Roche to Develop IBI3009 for SCLC

Innovent Biologics Collaborates with Roche to Develop IBI3009 for SCLC

ByRidhi RastogiJanuary 2, 20250Comments

Hutchmed

HUTCHMED Reports the NMPA’s NDA Acceptance of Orpathys Plus Tagrisso with Priority Review for EGFR-Mutated NSCLC with MET Amplification

ByRidhi RastogiJanuary 2, 20250Comments

Pfizer Teminates the Deal to Develop Giroctocogene Fitelparvovec for Hemophilia A with Sangamo Therapeutics

Pfizer Teminates the Deal to Develop Giroctocogene Fitelparvovec for Hemophilia A with Sangamo Therapeutics

BySenior EditorJanuary 1, 20250Comments

Galera Therapeutics Completes Nova Pharmaceuticals’ Acquisition

Galera Therapeutics Completes Nova Pharmaceuticals’ Acquisition

BySenior EditorJanuary 1, 20250Comments

ADC Therapeutics Reports Enrollment Completion in P-III (LOTIS-5) Study of Zynlonta Plus Rituximab for 2L+ Diffuse Large B-Cell Lymphoma

ADC Therapeutics Reports Enrollment Completion in P-III (LOTIS-5) Study of Zynlonta Plus Rituximab for 2L+ Diffuse Large B-Cell Lymphoma

BySenior EditorJanuary 1, 20250Comments

Xbrane Biopharma Reports Resubmission of BLA to the US FDA for Ranibizumab Biosimilar Candidate

Xbrane Biopharma Reports Resubmission of BLA to the US FDA for Ranibizumab Biosimilar Candidate

ByadminJanuary 1, 20250Comments

Corcept Therapeutics Reports NDA Submission of Relacorilant to the US FDA for Treating Hypercortisolism

Corcept Therapeutics Reports NDA Submission of Relacorilant to the US FDA for Treating Hypercortisolism

BySenior EditorJanuary 1, 20250Comments

Brii Bio Signs an Agreement with VBI Vaccines to Acquire BRII-179’s IP Rights

Brii Bio Signs an Agreement with VBI Vaccines to Acquire BRII-179’s IP Rights

BySenior EditorJanuary 1, 20250Comments

New Drug Designations - November 2024

New Drug Designations – November 2024

BySaurabh ChaubeyDecember 31, 20240Comments

Log in to your account